DFDA

Mifepristone

Treatment for Cushings Syndrome

Typical Dosage: 300-1200 mg daily

Effectiveness
50%
Safety Score
55%
Clinical Trials
10
Participants
500

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
55
DangerousModerateSafe
Treatment Details
Dosage Range
300-1200 mg daily
Time to Effect
6-12 weeks
Treatment Duration
lifetime
Evidence Quality
HIGH
Number Needed to Treat (NNT)
3.5(Treat 3.5 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
2.5(Treat 2.5 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$200,000
Monitoring:$2,000
Side Effect Mgmt:$1,500
Total Annual:$203,500
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POOR
ICER
$600,000/QALY
QALYs Gained
0.4
Outcome-Based Costs
Cost per Responder
$407,000
Mifepristone Outcomes

for Cushings Syndrome

Efficacy Outcomes
Overall Effectiveness
+50%
Response Rate
+50%
Common Side Effects
Hypokalemia
+45%
Nausea/Fatigue
+35%
Hypertension
+25%
Peripheral edema
+25%
Endometrial thickening/bleeding
+25%

Sources:

nih.gov
oup.com
elsevierpure.com

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
No active trials currently recruiting for this treatment

No active trials found in ClinicalTrials.gov

Completed Clinical Trials
7 completed trials for Mifepristone in Cushings Syndrome

Glucocorticoid Receptor Blockade With Mifepristone in Patients With Mild Adrenal Hypercortisolism

NCT01990560COMPLETEDPHASE4
View Study
8 participants
INTERVENTIONAL
New York, United States
Started: Nov 1, 2013

An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome

NCT00936741COMPLETEDPHASE3
View Study
30 participants
INTERVENTIONAL
Birmingham, United States +14 more
Started: Jul 1, 2009

A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome

NCT00569582COMPLETEDPHASE3
View Study
50 participants
INTERVENTIONAL
Birmingham, United States +16 more
Started: Dec 1, 2007

Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatment With Korlym® (Mifepristone) (CATALYST)

NCT05772169COMPLETEDPHASE4
View Study
1.11K participants
INTERVENTIONAL
Escondido, United States +35 more
Started: Mar 31, 2023

Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome

NCT01371565COMPLETEDPHASE3
View Study
4 participants
INTERVENTIONAL
Hollywood, United States +4 more
Started: Nov 1, 2010

Retrospective Chart Review Study of Korlym for the Treatment of ACTH Independent Cushing's Syndrome

NCT02663609COMPLETED
View Study
24 participants
OBSERVATIONAL
Started: Oct 1, 2015

Mifepristone Effects on Glucose Intolerance in Obese/Overweight Adults

NCT01419535COMPLETEDPHASE1, PHASE2
View Study
19 participants
INTERVENTIONAL
Bethesda, United States
Started: Nov 29, 2011